A pivotal study of MIP-1095-I-131
Latest Information Update: 13 Aug 2019
At a glance
- Drugs LNTH 1095 (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Progenics Pharmaceuticals
Most Recent Events
- 09 Aug 2019 According to an Progenics Pharmaceuticals media release, based on the early data emerging from the previous Phase 2 trial[700300636] and dialogue with the FDA, the company is planning to initiate this pivotal trial.
- 16 May 2019 New trial record
- 09 May 2019 According to a Progenics Pharmaceuticals media release, the company expects to initiate this study in 2020.